BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 20855960)

  • 81. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
    Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
    Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L; Dittmann J; Vogler M; Fulda S
    Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
    [TBL] [Abstract][Full Text] [Related]  

  • 83. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
    Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
    Qin JZ; Xin H; Sitailo LA; Denning MF; Nickoloff BJ
    Cancer Res; 2006 Oct; 66(19):9636-45. PubMed ID: 17018621
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [TBL] [Abstract][Full Text] [Related]  

  • 86. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells.
    Zhong D; Gu C; Shi L; Xun T; Li X; Liu S; Yu L
    J Cell Biochem; 2014 Sep; 115(9):1624-35. PubMed ID: 24788582
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
    Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
    Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
    [TBL] [Abstract][Full Text] [Related]  

  • 89. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
    Daressy F; Séguy L; Favre L; Corvaisier S; Apel C; Groo AC; Litaudon M; Dumontet V; Malzert-Fréon A; Desrat S; Roussi F; Robert A; Wiels J
    Biomed Pharmacother; 2022 Oct; 154():113546. PubMed ID: 35988426
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
    Satta T; Li L; Chalasani SL; Hu X; Nkwocha J; Sharma K; Kmieciak M; Rahmani M; Zhou L; Grant S
    Clin Cancer Res; 2023 Apr; 29(7):1332-1343. PubMed ID: 36652560
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
    Skoda C; Erovic BM; Wachek V; Vormittag L; Wrba F; Martinek H; Heiduschka G; Kloimstein P; Selzer E; Thurnher D
    Oncol Rep; 2008 Jun; 19(6):1499-503. PubMed ID: 18497956
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Chuckalovcak J; Stringer DK; Koromilas AE; Boone DL; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(17):23608-32. PubMed ID: 27015562
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1.
    Duffin R; Leitch AE; Sheldrake TA; Hallett JM; Meyer C; Fox S; Alessandri AL; Martin MC; Brady HJ; Teixeira MM; Dransfield I; Haslett C; Rossi AG
    FEBS Lett; 2009 Aug; 583(15):2540-6. PubMed ID: 19616548
    [TBL] [Abstract][Full Text] [Related]  

  • 94. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
    Lang JY; Hsu JL; Meric-Bernstam F; Chang CJ; Wang Q; Bao Y; Yamaguchi H; Xie X; Woodward WA; Yu D; Hortobagyi GN; Hung MC
    Cancer Cell; 2011 Sep; 20(3):341-56. PubMed ID: 21907925
    [TBL] [Abstract][Full Text] [Related]  

  • 95. BH3-mimetics- and cisplatin-induced cell death proceeds through different pathways depending on the availability of death-related cellular components.
    Andreu-Fernández V; Genovés A; Messeguer A; Orzáez M; Sancho M; Pérez-Payá E
    PLoS One; 2013; 8(2):e56881. PubMed ID: 23437261
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor.
    Lindqvist LM; Vikström I; Chambers JM; McArthur K; Ann Anderson M; Henley KJ; Happo L; Cluse L; Johnstone RW; Roberts AW; Kile BT; Croker BA; Burns CJ; Rizzacasa MA; Strasser A; Huang DC
    Cell Death Dis; 2012 Oct; 3(10):e409. PubMed ID: 23059828
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
    Halatsch ME; Kast RE; Dwucet A; Hlavac M; Heiland T; Westhoff MA; Debatin KM; Wirtz CR; Siegelin MD; Karpel-Massler G
    Br J Pharmacol; 2019 Sep; 176(18):3681-3694. PubMed ID: 31222722
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
    Wang K; Hampson P; Hazeldine J; Krystof V; Strnad M; Pechan P; M J
    PLoS One; 2012; 7(1):e30128. PubMed ID: 22276149
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
    Nowsheen S; Cooper T; Stanley JA; Yang ES
    PLoS One; 2012; 7(10):e46614. PubMed ID: 23071597
    [TBL] [Abstract][Full Text] [Related]  

  • 100. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy.
    Heidari N; Hicks MA; Harada H
    Cell Death Dis; 2010 Sep; 1(9):e76. PubMed ID: 21364679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.